Immunotherapy with recombinant human interleukin-2 and recombinant interferon-α in lymphoma patients postautologous marrow or stem cell transplantation

Blood

Volumn 89, Issue 11, 1997, Pages 3951-3959

  Nagler, A ^a   Ackerstein, A ^a   Or, R ^a   Naparstek, E ^a   Slavin, S ^a  

^a HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ALPHA INTERFERON; RECOMBINANT INTERLEUKIN 2;

ADOLESCENT; ADULT; ADVANCED CANCER; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER STAGING; CHILD; CONTROLLED STUDY; DEMOGRAPHY; FEMALE; FOLLOW UP; HUMAN; IMMUNE RESPONSE; MAJOR CLINICAL STUDY; MALE; MINIMAL RESIDUAL DISEASE; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; REMISSION; STEM CELL TRANSPLANTATION; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 0030969519     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v89.11.3951     Document Type: Article

References (78)

1. McMillan AK, Goldstone AH: Autologous bone marrow transplantation non-Hodgkin's lymphoma. Eur J Haematol 46:129, 1991
2. Gale RP, Armitage JO, Dicke KA: Autotransplants: Now and in the future. Bone Marrow Transplant 7:153, 1991
3. Freedman AS, Takvorian T, Neuberg D, Mauch P, Rabinowe SN, Anderson KC, Soiffer RJ, Spector N, Grossbard M, Robertson MJ, Blake K, Coral F, Canellos GP, Ritz J, Nadler LM: Autologous bone marrow transplantation in poor-prognosis intermediate-grade and high-grade B-cell non-Hodgkin's lymphoma in first remission: A pilot study. J Clin Oncol 11:931, 1993
4. Phillips GL, Fay JW, Herzig RH, Lazarus HM, Wolff SN, Lin HS, Shina DC, Glasgow GP, Griffith RC, Lamb CW, Herzig GP: The treatment of progressive non-Hodgkin's lymphoma with intensive chemoradiotherapy and autologous marrow transplantation. Blood 75:831, 1990
5. Loiseau HA, Hartmann O, Valteau D, McDowell H, Brugieres L, Vassal G, Kalifa C, Patte C, Lemerle J: High-dose chemotherapy containing busulfan followed by bone marrow transplantation in 24 children with refractory or relapsed non-Hodgkin's lymphoma. Bone Marrow Transplant 8:465, 1991
6. Chopra R, Goldstone AH, Pearce R, Philip T, Petersen F, Appelbaum F, De Vol E, Ernst P: Autologous versus allogeneic bone marrow transplantation for non-Hodgkin's lymphoma: A case-controlled analysis of the European Bone Marrow Transplant Group Registry Data. J Clin Oncol 10:1690, 1992
7. Shipp MA: Prognostic factors in aggressive non-Hodgkin's lymphoma: Who has "high-risk" disease? Blood 83:1165, 1994
8. Freedman A, Nadler LM: Bone marrow transplantation in low-grade non-Hodgkin's lymphoma. Marrow Transplant Rev 2:39, 1992
9. Yahalom J, Gulati S, Shank B, Clarkson B, Fuks Z: Total lymphoid irradiation, high-dose chemotherapy and autologous bone marrow transplantation for chemotherapy-resistant Hodgkin's disease. Int J Radiat Oncol Biol Phys 17:915, 1989
10. Reece DE, Connors JM, Spinelli JJ, Barnett MJ, Fairey RN, Klingemann HG, Nantel SH, O'Reilly S, Shepherd JD, Sutherland HJ, Voss N, Chan KW, Phillips GL: Intensive therapy with cyclophosphamide, carmustine, etoposide + cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. Blood 83:1193, 1994
11. Chopra R, McMillan AK, Linch DC, Yuklea S, Taghipour G, Pearce R, Patterson KG, Goldstone AH: The place of high-dose BEAM therapy and autologous bone marrow transplantation in poor-risk Hodgkin's disease. A single-center eight-year study of 155 patients. Blood 81:1137, 1993
12. Bierman PJ, Vose JM, Armitage JO: Autologous transplantation for Hodgkin's disease: Coming of age? Blood 83:1161, 1994
13. Slavin S, Nagler A: New developments in bone marrow transplantation. Curr Opin Oncol 3:254, 1991
14. Slavin S, Ackerstein A, Vourka-Karussis U, Nagler A, Or R, Naparstek E, Weiss L: Control of relapse due to minimal residual disease (MRD) by cell-mediated cytokine-activated immunotherapy in conjunction with bone marrow transplantation. Bailliere's Clin Haematol 4:715, 1991
15. Mehta J: Graft-versus-leukemia reactions in clinical bone marrow transplantation. Leuk Lymphoma 10:427, 1993
16. Slavin S, Ackerstein A, Naparstek E, Or R, Weiss L: The graft-versus-leukemia (GVL) phenomenon: Is GVL separable from GVHD? Bone Marrow Transplant 6:155, 1990
17. Moscovitch M, Slavin S: Anti tumor effects of allogeneic bone marrow transplantation in (NZB × NZW) F1 hybrids with spontaneous lymphosarcoma. J Immunol 132:997, 1984
18. Phillips GL, Herzig RH, Lazarus HM, Fay JW, Griffith R, Herzig GP: High dose chemotherapy, fractionated total body irradiation and allogeneic marrow transplantation for malignant lymphoma. J Clin Oncol 4:480, 1986
19. Ernst P, Devol E: Allogeneic bone marrow transplantation in malignant lymphoma. The European Bone Marrow Transplant Group experience. Proceedings of the 4th International Conference Lymphoma, Lugano, Switzerland, June 9-12, 1990 (abstr P35)
20. Jones RJ, Ambinder RF, Piantadosi S, Santos GW: Evidence of a graft-versus-lymphoma effect associated with allogeneic bone marrow transplantation. Blood 77:649, 1991
21. Fujimiya Y, Bakke A, Chang WC, Linker-Israeli M, Udis B, Horwitz D, Pattengale PK: Natural killer-cell immunodeficiency in patients with chronic myelogenous leukemia: I. Analysis of the defect using the monoclonal antibodies HNK-I (LEU-7) and B73.1. Int J Cancer 37:639, 1986
22. Dutcher JP, Creekmore S, Weiss GR, Margolin K, Markowitz AB, Roper M, Parkinson D, Ciobanu N, Fisher RI, Boldt DDH, Doroshow JH, Rayner AA, Hawkins M, Atkins M: A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma. J Clin Oncol 7:477, 1989
23. Gilewski TA, Richards JM: Biologic response modifiers in non-Hodgkin's lymphomas. Semin Oncol 17:74, 1990
24. Quesada JR, Talpaz M, Rios A Kurzrock R, Gutterman JU: Clinical toxicity of interferons in cancer patients: A review. J Clin Oncol 4:234, 1986
25. McLaughlin P: The role of interferon in the therapy of low grade lymphoma. Leuk Lymphoma 10:17, 1993 (suppl)
26. Smalley RV, Andersen JW, Hawkins MJ, Bhide V, O'Connell MJ, Oken MM, Borden EC: Interferon alfa combined with cytotoxic chemotherapy for patients with non-Hodgkin's lymphoma. N Engl J Med 327:1336, 1992
27. Nagler A, Lanier LL, Cwirla S, Philips JH: Comparative studies of human FcRIII-positive and negative NK cells. J Immunol 143:3183, 1989
28. Nagler A, Lanier L, Phillips JH: Constitutive expression of high affinity interleukin-2 receptors on human CD16-natural killer cells in vivo. J Exp Med 171:1527, 1990
29. Ackerstein A, Kedar E, Slavin S: Use of recombinant interleukin-2 in conjunction with syngeneic bone marrow transplantation in mice as a model for control of minimal residual disease in malignant hematological disorders. Blood 78:1212, 1991
30. Slavin S, Ackerstein A, Weiss L: Adoptive immunotherapy in conjunction with bone marrow transplantation amplification of natural host defence mechanisms against cancer by recombinant IL2. Natl Immun Cell Growth Regul 7:180, 1988
31. Dutcher JP, Wiernik PH: The role of recombinant interleukin-2 therapy for hematologic malignancies. Semin Oncol 20:33, 1993
32. Duggan DB, Santarell MT, Zamkoff K, Lichtman S, Ellerton J, Cooper R, Poiesz B, Anderson JR, Bloomfield CD, Peterson BA: A phase II study of recombinant interleukin-2 with or without recombinant interferon-β in non-Hodgkin's lymphoma. A study of cancer and leukemia group B. Br J immunother 12:115, 1992
33. Bernstein ZP, Vaickus L, Friedman N, Goldrosen MH, Watanabe H, Rahmam R, Arbuck SG, Sweeney J, Vesper D, Henderson ED: Interleukin-2 lymphokine-activated killer cell therapy of non-Hodgkin's lymphoma and Hodgkin's disease. J Immunother 10:141, 1991
34. Lim SH, Worman CP, Callaghan T, Jewell A, Smith MP, Goldstone AH: Continuous intravenous infusion of high dose recombinant interleukin-2 for advanced lymphomas: A phase II study. Leuk Res 15:435, 1991
35. Weber JS, Yang JC, Topalian SL, Schwartzentruben DJ, White DE, Rosenberg SA: The use of Interleukin-2 and lymphokine-activated killer cells for the treatment of patients with non-Hodgkin's lymphoma. J Clin Oncol 10:33, 1992
36. Gisselbrecht C, Maraninchi D, Pico JL, Milpied N, Coiffier B, Divine M, Tiberghien P, Bosly A, Tilly H, Boulat O, Brandely M: Interleukin-2 treatment in lymphoma: A phase II multicenter study. Blood 83:2081, 1994
37. Morecki S, Nagler A, Puyesky Y, Nabet C, Condiotti R, Pick M, Gan S, Slavin S: Effect of various cytokine combinations on induction of non-MHC-restricyted cytotoxicity. Lymphokine Cytokine Res 12:159, 1993
38. Morecki S, Revel-Vilk S, Nabet C, Pick M, Ackerstein A, Nagler A, Naparstek E, Ben Shahar M, Slavin S: Immunological evaluation of patients with hematological malignancies receiving ambulatory cytokine-mediated immunotherapy with recombinant human interferon-α2a and interleukin-2. Cancer Immunol Immunother 35:401, 1992
39. Brunda MJ, Tarnowski D, Davatelis V: Interaction of recombinant interferons with recombinant interleukin-2: Differential effects on natural killer cell activity and interleukin-2-activated killer cells. Int J Cancer 37:787, 1986
40. Brunda MJ, Beffantoni D, Sulich V: In vivo antitumor activity of combinations of interferon alpha and interleukin-2 in a murine model. Correlation of efficacy with the induction of cytotoxic cells resembling natural killer cells. Int J Cancer 40:365, 1987
41. Iigio M, Sakurai M, Tamura T, Saijo N: In vivo antitumor activity of multiple injections of recombinant interleukin 2, alone and in combination with three different types of recombinant interferon, on various syngeneic murine tumors. Cancer Res 48:260, 1988
42. Kuribayashi K, Gillis S, Kern DE, Henney CS: Murine NK cell cultures: Effects of interleukin-2 and interferon on cell growth and cytotoxic reactivity. J Immunol 126:2321, 1981
43. Nagler A, Ackerstein A, Barak V, Slavin S: Treatment of chronic myejogenous leukemia with recombinant human interleukin-2 and interferon-α2a. J Hematother 3:75, 1994
44. Fefer A, Benyunes M, Higuchi C, York A, Massumoto C, Lindgren C, Buckner CD, Thompson JA: Interleukin-2 +/-lymphocytes as consolidative immunotherapy after autologous bone marrow transplantation for hematologic malignancies. Acta Hematol 89:2, 1993 (suppl 1)
45. Fefer A, Benyunes M, Massumoto C, Higuchi C, York A, Buckner CD, Thompson JA: Interleukin-2 therapy after autologous bone marrow transplantation for hematologic malignancies. Semin Oncol 20:41, 1993
46. Slavin S, Ackerstein A, Weiss L, Nagler A, Or R, Naparstek E: Immunotherapy of minimal residual disease by immunocompetent lymphocytes and their activation by cytokines. Cancer Invest 10:221, 1992
47. Weiss L, Reich S, Slavin S: Use of recombinant human interleukin-2 in conjunction with bone marrow transplantation as a model for control of minimal residual disease in malignant hematological disorders: I. Treatment of murine leukemia in conjunction with allogeneic bone marrow transplantation and IL-2-activated cell-mediated immunotherapy. Cancer Invest 10:19, 1992
48. Cohen P, Vourka-Karussis U, Weiss L, Slavin S: Spontaneous and IL-2-induced anti-leukemic and anti-host effects against tumor-and host-specific alloantigens. J Immunol 151:4803, 1993
49. Vourka-Karussis U, Karussis D, Ackerstein A, Sfavin S: Enhancement of GVL effect with rhIL-2 following BMT in a murine model for acute myeloid leukemia in SJL/J mice. Exp Hematol 23:196, 1995
50. Cox DR: Regression models and life tables. JR Stat Soc B 34:187, 1972
51. Kadar E, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457, 1958
52. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163, 1966
53. Klapholz L, Ackerstein A, Goldenhersh MA, Vardy D, Nagler A: Local cutaneous reaction induced by subcutaneous interleukin-2 and interferon alpha-2a immunotherapy following ABMT. Bone Marrow Transplant 11:443, 1993
54. Schechter D, Nagler A, Ackerstein A, Nassar H, Admon D, Naparstek E, Rein AJ: Recombinant interleukin-2 and interferon alpha immunotherapy following autologous bone marrow transplantation. A case report. Cardiology 80:168, 1992
55. Schechter D, Nagler A: Recombinant interleukin-2 and recombinant alpha immunotherapy cardiovascular toxicity. Am Heart J 123:1736, 1992 (editorial)
56. Slavin S, Naparstek E, Nagler A, Ackerstein A, Kapelushnik J, Or R: Allogeneic cell therapy for relapsed leukemia after bone marrow transplantation with donor peripheral blood lymphocytes. Exp Hematol 23:1553, 1995
57. Basham TY, Merigan TC: Recombinant interferon-gamma increases HLA-DR synthesis and expression. J Immunol 130:1492, 1983
58. Lum LG: The kinetics of immune reconstitution after human marrow transplantation. Blood 69:369, 1987
59. Azogui O, Gluckman E, Fradelizi D: Inhibition of IL-2 production after human allogeneic bone marrow transplantation. J Immunol 131:1205, 1983
60. Weite K, Ciobanu N, Moore MA, Gulati S, O'Reiuy RJ, Mertelsmann R: Defective interleukin-2 production in patients after bone marrow transplantation and in vitro restoration of defective T lymphocyte proliferation by highly purified interleukin-2. Blood 64:380, 1984
61. Cayeux S, Meuer S, Pezzutto A, Korbling M, Haas R, Schulz R, Dorken B: T-cell ontogeny after autologous bone marrow transplantation: Failure to synthesize interleukin-2 (IL-2) and lack of CD2- and CD3-mediated proliferation by both CD4-and CD8+ cells even in the presence of exogeneous IL-2. Blood 74:2270, 1989
62. Bosly A, Brice P, Humblet Y, Doyen C, Faille A, Chatelain B, Franks C, Gisselbrecht C, Symann M: Interleukin-2 after autologous bone marrow transplantation as consolidative immunotherapy against minimal residual disease. Nouv Rev Fr Hematol 32:13, 1990
63. Klingemann H-G, Phillips GL: Is there a place for immunotherapy with interleukin-2 to prevent relapse after autologous stem cell transplantation for acute leukemia? Leuk Lymphoma 16:397, 1995
64. Weisdorf DJ, Anderson PM, Biazar BR, Uckun FM, Kersey JH, Ramsay NK: Interleukin-2 immediately after autologous bone marrow transplantation for acute lymphoblastic leukemia. A phase I study. Transplantation 55:61, 1993
65. Negrier S, Ranchere JY, Philip I. Merrouche Y, Biron P, Blaise D, Attal M, Rebattu P, Clavel M, Fourreau C, Palmer P, Favrot M, Jasmin C, Maraninchi D, Philip T: Intravenous interleukin-2 just after high dose BCNU and autologous bone marrow transplantation. Report of a multicentric French pilot study. Bone Marrow Transplant 8:259, 1991
66. Blaise D, Olive D, Stoppa AM, Viens P, Pourreau C, Lopez M, Attal M, Jasmin D, Mognes G, Mawas C, Mannoni P, Palmer P, Franks C, Philip T, Maraninch D: Hematologic and immunologic effects of the systemic administration of recombinant interleukin-2 after autologous bone marrow transplantation. Blood 76:1092, 1990
67. Blaise D, Viens P, Olive D, Stoppa AM, Gabert J, Pourreau CN, Attal M, Gaspard MH, Mannoni P, Jasmin C, Palmer P, Franks C, Michel G, Mawas C, Baume D, Philip T, Maraninchi D: Recombinant interleukin-2 (rIL-2) after autologous bone marrow transplantation (BMT): A pilot study in 19 patients. Eur Cytokine Netw 2:121, 1991
68. Higuchi CM, Thompson JA, Cox T, Lindgren CG, Buckner D, Fefer, A: Lymphokine-activated killer function following autologous bone marrow transplantation for refractory hematological malignancies. Cancer Res 59:5509, 1989
69. Higuchi CM, Thompson JA, Petersen FB, Buckner CD, Fefer A: Toxicity and immunomodulatory effects of interleukin-2 after autologous bone marrow transplantation for hematologic malignancies. Blood 77:2561, 1991
70. Bosly A, Guillaume T, Brice P, Humblet Y, Staquet P, Doyen C, Chatelain B, Franks CR, Gisselbrecht C, Symann M: Effects of escalating doses of recombinant human interleukin-2 in correcting functional T-cell defects following autologous bone marrow transplantation for lymphomas and solid tumors. Exp Hematol 20:962, 1992
71. Klingemann HG, Grigg AP, Wilkie-Boyd K, Barnett MJ, Eaves AC, Reece DE, Shepherd JD, Phillips GL: Treatment with recombinant interferon (α-2b) early after bone marrow transplantation in patients at high risk for relapse. Blood 78:3306, 1991
72. Vivancos P, Granena A, Garcia J, Abad B, VaUs A: Post-ABMT treatment with high doses of IL2 and IFN. Results of a phase II study. Proceedings of the 19th Annual Meeting of the EBMT and 9th Meeting of the Nurses Group. Garmisch-Partenkirchen, Germany, January 17, 1993, p 123 (abstr)
73. Atzpodien J, Korfer A, Franks CR, Poliwoda H, Kirchrer H: Home therapy with recombinant interleukin-2 and interferon-α2b in advanced human malignancies. Lancet 335:1509, 1990
74. Hirsh M, Lipton A, Harvey H, Givant E, Hopper K, Jones G, Zeffren J, Levitt D: Phase I study of interleukin-2 and interferon alfa-29 as outpatient therapy for patients with advanced malignancy. J Clin Oncol 8:1657, 1990
75. Lee KH, Talpaz M, Rotherberg JM, Murray JL Papadopoulos N, Plager C, Benjamin R, Levitt D, Gutterman J: Concomitant administration of recombinant human interleukin-2 and recombinant interferon α-2A in cancer patients: A phase I study. J Clin Oncol 17:1726, 1989
76. Radhakrishna Pillai M, Balaram P, Padmanabhan TK, Abraham T, Krishnan Nair M: Interleukin 2 and alpha interferon induced in vitro modulation of spontaneous cell mediated cytotoxicity in patients with cancer of the uterine cervix undergoing radiotherapy. Acta Oncol 28:39, 1989
77. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE: Combination therapy with interleukin-2 and alpha-interferon for the treatment of patients with advanced cancer. J Clin Oncol 7:1863, 1989
78. Rabinowitz J, Petros W, Stuart A, Peters W: Characterization of endogenous cytokine concentration after high dose chemotherapy with autologous bone marrow support. Blood 81:2452, 1993